Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma

We previously developed a method for determining MYCN gene amplification status using cell-free DNA fragments released from cancer cells into the blood of patients with neuroblastoma (NB). Here, we analyzed the relationship between MYCN amplification (MNA) status and neuroblastoma prognosis. We scre...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-08, Vol.11 (8), p.e0161039-e0161039
Main Authors: Yagyu, Shigeki, Iehara, Tomoko, Tanaka, Shiro, Gotoh, Takahiro, Misawa-Furihata, Akiko, Sugimoto, Tohru, London, Wendy B, Hogarty, Michael D, Teramukai, Satoshi, Nakagawara, Akira, Hiyama, Eiso, Maris, John M, Hosoi, Hajime
Format: Article
Language:English
Subjects:
Age
Amplification
Bioindicators
Biology and Life Sciences
Biomarkers
Biomarkers - blood
Biopsy
Cancer
Children & youth
Computer centers
Confidence intervals
Deoxyribonucleic acid
Diagnosis
DNA
DNA methylation
Female
Gene Amplification
Genetic aspects
Hospitals
Humans
Infant
Male
Medical diagnosis
Medical prognosis
Medical research
Medicine
Medicine and Health Sciences
Metabolites
Mortality
MYCN gene
N-Myc Proto-Oncogene Protein - blood
N-Myc Proto-Oncogene Protein - genetics
Neuroblastoma
Neuroblastoma - blood
Neuroblastoma - diagnosis
Neuroblastoma - genetics
Oncology
Patients
Pediatrics
Physical Sciences
Physiological aspects
Prognosis
Real-Time Polymerase Chain Reaction
Risk allocation
Science
Sensitivity
Sensitivity analysis
Serum albumin
Studies
Survival
Survival Rate
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We previously developed a method for determining MYCN gene amplification status using cell-free DNA fragments released from cancer cells into the blood of patients with neuroblastoma (NB). Here, we analyzed the relationship between MYCN amplification (MNA) status and neuroblastoma prognosis. We screened serum samples from 151 patients with NB for MNA, using real-time quantitative PCR, and compared the results with MYCN status determined using paired tumor samples. We additionally investigated whether MNA status correlates with patient survival. When a cut-off value of 5 was used, serum-based MNA analysis was found to show good sensitivity (86%) and very high specificity (95%). The sensitivities for stage 1 and 2 might be acceptable, even though it is not as good as for stage 3 and 4 (67% for stage 1 and 2, 92% for stage 3, and 87% for stage 4). MNA status correlated with overall survival in our cohort of 82 patients, with survival data available (p < 0.01). The hazard ratio of MNA status was 4.98 in patients diagnosed at less than 18 months of age (95% confidence interval, 1.00-24.78), and 1.41 (95% confidence interval, 0.63-3.14) for those diagnosed at 18 months of age or older. Serum-based MNA analysis is rapid and non-invasive compared with tumor-based MNA analysis, and has potential to predict tumor MNA status. There is still a room to improve the sensitivity of the test for tumors of stages 1 and 2, nonetheless this assay might help to determine therapeutic strategies prior to tumor biopsy, especially for patients with a life-threatening condition, as well as for patients of less than 18 months of age whose risk-grouping and treatment allocation depends on their MNA status.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0161039